Activated mouse eosinophils protect against lethal respiratory virus infection

Blood

Volumn 123, Issue 5, 2014, Pages 743-752

  Percopo, Caroline M ^a   Dyer, Kimberly D ^a   Ochkur, Sergei I ^b   Luo, Janice L ^a   Fischer, Elizabeth R ^c   Lee, James J ^b   Lee, Nancy A ^b   Domachowske, Joseph B ^d   Rosenberg, Helene F ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CONTROLLED STUDY; DEGRANULATION; EOSINOPHIL; LUNG ASPERGILLOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VIRAL RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA; ANIMAL; ASPERGILLUS FUMIGATUS; C57BL MOUSE; FEMALE; IMMUNOLOGY; LUNG; MALE; MICROBIOLOGY; MURINE PNEUMONIA VIRUS; PHYSIOLOGY; PNEUMOVIRUS INFECTION; VIROLOGY;

ANIMALS; ASPERGILLUS FUMIGATUS; ASTHMA; CELL DEGRANULATION; EOSINOPHILS; FEMALE; LUNG; MALE; MICE; MICE, INBRED C57BL; MURINE PNEUMONIA VIRUS; OVALBUMIN; PNEUMOVIRUS INFECTIONS;

EID: 84894044993     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-502443     Document Type: Article

References (49)

1. Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J. 2009;3(4):198-206.
2. Lin TY, Poon AH, Hamid Q. Asthma phenotypes and endotypes. Curr Opin Pulm Med. 2013;19(1):18-23.
3. Barbato A, Turato G, Baraldo S, et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med. 2003;168(7):798-803. (Pubitemid 37188303)
4. Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics. 2013;7:7-11.
5. Castro M, Mathur S, Hargreave F, et al; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-1132.
6. Thomas A, Busse W. The evolving role of eosinophils in asthma. In: Lee JJ, Rosenberg HF, eds. Eosinophils in Health and Disease. Waltham, MA: Elsevier; 2012:448-461.
7. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9-22.
8. Rosenberg HF, Dyer KD, Domachowske JB. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res. 2009;83(1):1-9.
9. Rosenberg HF, Domachowske JB. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol. 2001;70(5):691-698. (Pubitemid 33127003)
10. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med. 1999;159(6):1918-1924. (Pubitemid 29275064)
11. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis. 1998;177(6):1458-1464. (Pubitemid 28243566)
12. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res. 1998;26(14):3358-3363. (Pubitemid 28321399)
13. Adamko DJ, Yost BL, Gleich GJ, Fryer AD, Jacoby DB. Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects. J Exp Med. 1999;190(10):1465-1478.
14. Phipps S, Lam CE, Mahalingam S, et al. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood. 2007;110(5):1578-1586. (Pubitemid 47443974)
15. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol. 2011;301(2):L148-L156.
16. Rosenberg HF, Bonville CA, Easton AJ, Domachowske JB. The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention. Pharmacol Ther. 2005;105(1):1-6. (Pubitemid 40038869)
17. Dyer KD, Garcia-Crespo KE, Glineur S, Domachowske JB, Rosenberg HF. The Pneumonia Virus of Mice (PVM) model of acute respiratory infection. Viruses. 2012;4(12):3494-3510.
18. Glineur SF, Renshaw RW, Percopo CM, et al. Novel pneumoviruses (PnVs): Evolution and inflammatory pathology. Virology. 2013;443(2):257-264.
19. Ochkur SI, Jacobsen EA, Protheroe CA, et al. Coexpression of IL-5 and eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. J Immunol. 2007;178(12):7879-7889. (Pubitemid 46898060)
20. Filley WV, Holley KE, Kephart GM, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet. 1982;2(8288):11-16. (Pubitemid 12124112)
21. Shahana S, Björnsson E, Lúdvíksdóttir D, et al; BHR-group. Ultrastructure of bronchial biopsies from patients with allergic and non-allergic asthma. Respir Med. 2005;99(4):429-443. (Pubitemid 40347826)
22. Yu C, Cantor AB, Yang H, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002;195(11):1387-1395. (Pubitemid 34602816)
23. Ochkur SI, Kim JD, Protheroe CA, et al. The development of a sensitive and specific ELISA for mouse eosinophil peroxidase: assessment of eosinophil degranulation ex vivo and in models of human disease. J Immunol Methods. 2012;375(1-2):138-147.
24. Moreau JM, Dyer KD, Bonville CA, et al. Diminished expression of an antiviral ribonuclease in response to pneumovirus infection in vivo. Antiviral Res. 2003;59(3):181-191. (Pubitemid 36966750)
25. Rosenberg HF, Domachowske JB. Eosinophil-derived neurotoxin. Methods Enzymol. 2001;341:273-286. (Pubitemid 32928532)
26. Gabryszewski SJ, Bachar O, Dyer KD, et al. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J Immunol. 2011;186(2):1151-1161.
27. Malm-Erjefält M, Persson CG, Erjefält JS. Degranulation status of airway tissue eosinophils in mouse models of allergic airway inflammation. Am J Respir Cell Mol Biol. 2001;24(3):352-359. (Pubitemid 32228385)
28. Stelts D, Egan RW, Falcone A, et al. Eosinophils retain their granule major basic protein in a murine model of allergic pulmonary inflammation. Am J Respir Cell Mol Biol. 1998;18(4):463-470. (Pubitemid 128353619)
29. Denzler KL, Borchers MT, Crosby JR, et al. Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation. J Immunol. 2001;167(3):1672-1682. (Pubitemid 32703170)
30. Denzler KL, Farmer SC, Crosby JR, et al. Eosinophil major basic protein-1 does not contribute to allergen-induced airway pathologies in mouse models of asthma. J Immunol. 2000;165(10):5509-5517.
31. Lee JJ, Lee NA. Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function? Clin Exp Allergy. 2005;35(8):986-994. (Pubitemid 41603131)
32. Kumar RK, Foster PS. Are mouse models of asthma appropriate for investigating the pathogenesis of airway hyper-responsiveness? Front Physiol. 2012;3:312.
33. Shin YS, Takeda K, Gelfand EW. Understanding asthma using animal models. Allergy Asthma Immunol Res. 2009;1(1):10-18.
34. Lacy P, Moqbel R. Signaling and degranulation. In: Lee JJ, Rosenberg HF, eds. Eosinophils in Health and Disease. Waltham, MA: Elsevier; 2012:206-218.
35. Melo RC, Spencer LA, Perez SA, et al. Vesicle-mediated secretion of human eosinophil granule-derived major basic protein. Lab Invest. 2009;89(7):769-781.
36. Tsuchiya K, Siddiqui S, Risse PA, Hirota N, Martin JG. The presence of LPS in OVA inhalations affects airway inflammation and AHR but not remodeling in a rodent model of asthma. Am J Physiol Lung Cell Mol Physiol. 2012;303(1):L54-L63.
37. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002;277(42):39320-39326. (Pubitemid 35190904)
38. Braedel S, Radsak M, Einsele H, et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol. 2004;125(3):392-399. (Pubitemid 38621772)
39. Millien VO, Lu W, Shaw J, et al. Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science. 2013;341(6147):792-796.
40. Kvarnhammar AM, Cardell LO. Eosinophil responses to pathogen-associated and damage-associated molecular patterns. In: Lee JJ, Rosenberg HF, eds. Eosinophils in Health and Disease. Waltham, MA: Elsevier; 2012:219-228.
41. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest. 2003;111(12):1863-1874. (Pubitemid 38057731)
42. Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood. 2009;114(13):2649-2656.
43. Davoine F, Cao M, Wu Y, et al. Virus-induced eosinophil mediator release requires antigen-presenting and CD41 T cells. J Allergy Clin Immunol. 2008;122(1):69-77, e1-e2.
44. Bonville CA, Easton AJ, Rosenberg HF, Domachowske JB. Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J Virol. 2003;77(2):1237-1244. (Pubitemid 36055547)
45. Bonville CA, Lau VK, DeLeon JM, et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J Virol. 2004;78(15):7984-7989. (Pubitemid 38944283)
46. Akuthota P, Wang HB, Spencer LA, Weller PF. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clin Exp Allergy. 2008;38(8):1254-1263. (Pubitemid 352019674)
47. Jacobsen EA, Taranova AG, Lee NA, Lee JJ. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J Allergy Clin Immunol. 2007;119(6):1313-1320. (Pubitemid 46855871)
48. Yang D, Rosenberg HF, Chen Q, Dyer KD, Kurosaka K, Oppenheim JJ. Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood. 2003;102(9):3396-3403. (Pubitemid 37314782)
49. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013;12(2):117-129.